Johnson & Johnson Forecasts Profit Growth Despite Drug Pricing Deal

In-Depth Analysis

### Background Johnson & Johnson has been navigating a complex landscape of patent expirations, pricing pressures, and legal challenges. The company's Q4 earnings and 2026 forecast provide insights into how it is managing these challenges and positioning itself for future success.

### Sales and Profit Growth J&J's Q4 results showed a 9.1% increase in sales, reaching $24.56 billion, which surpassed analysts' estimates of $24.15 billion. Net earnings rose 20.8% to $5.12 billion, or $2.10 a share. The Innovative Medicine division saw a 10% increase in sales, while the medical devices business grew by 7.5%.

### Impact of Stelara and New Drugs The loss of patent protection for Stelara led to a nearly 48% plunge in its sales during the fourth quarter. However, strong growth in sales of newer drugs like Darzalex and Tremfya helped cushion the impact. This highlights J&J's successful strategy of developing and commercializing new products to offset revenue losses from patent expirations.

### Drug Pricing Deal and Tariffs J&J's CFO, Joseph Wolk, mentioned that a drug pricing deal with the Trump administration would cost the company hundreds of millions of dollars in annual sales. Additionally, tariff costs for 2026 are expected to double to around $500 million. Despite these challenges, J&J remains confident in its ability to achieve sales growth of over 6% for 2026.

### Stock Performance J&J shares have risen approximately 48% over the past 12 months, giving the company a market capitalization of over $500 billion. This strong stock performance reflects investor confidence in J&J's ability to navigate challenges and deliver growth.

Read source article

FAQ

How will the drug pricing deal with the Trump administration impact J&J?

J&J expects the drug pricing deal to cost the company hundreds of millions of dollars in annual sales, but it believes it can absorb the impact and still forecast sales growth.

What is driving J&J's sales growth?

Strong sales of newer drugs, particularly those for cancer and autoimmune conditions, are driving J&J's sales growth. Darzalex and Tremfya are key contributors.

How is J&J dealing with competition from biosimilars?

J&J is focusing on developing and commercializing new products to offset revenue losses from patent expirations and biosimilar competition. The company's pipeline of new drugs is helping to mitigate the impact.

Takeaways

J&J is demonstrating resilience in the face of patent expirations and pricing pressures.
The company's diversified portfolio and successful development of new drugs are key drivers of its growth.
Investors should pay attention to J&J's ability to navigate challenges and maintain its strong market position.

Discussion

Do you think this trend will last? Let us know!

Share this article with others who need to stay ahead of this trend!

Sources

Johnson & Johnson forecasts 2026 profit above Wall Street estimates J&J wants to be the leader in the cancer fight. Its strategy is starting to pay off as oncology sales top $25 billion in 2025 J&J’s Sales and Profit Rise on Strong Cancer and Autoimmune Drug Sales

Disclaimer

This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.

All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.

This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.

Always do your own research (DYOR) before making any decisions based on the information presented.